David A. Ramsay
2013
In 2013, David A. Ramsay earned a total compensation of $1.7M as Vice President and Chief Financial Officer at Halozyme Therapeutics, a 217% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $201,413 |
|---|---|
| Option Awards | $593,176 |
| Salary | $314,941 |
| Stock Awards | $563,453 |
| Other | $8,122 |
| Total | $1,681,105 |
Ramsay received $593.2K in option awards, accounting for 35% of the total pay in 2013.
Ramsay also received $201.4K in non-equity incentive plan, $314.9K in salary, $563.5K in stock awards and $8.1K in other compensation.
Rankings
In 2013, David A. Ramsay's compensation ranked 4,511th out of 12,286 executives tracked by ExecPay. In other words, Ramsay earned more than 63.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,511 out of 12,286 | 63rd |
Division Manufacturing | 1,543 out of 4,612 | 67th |
Major group Chemicals And Allied Products | 440 out of 1,462 | 70th |
Industry group Drugs | 305 out of 1,156 | 74th |
Industry Biological Products, Except Diagnostic Substances | 46 out of 196 | 77th |
Source: SEC filing on March 23, 2016.
Ramsay's colleagues
We found five more compensation records of executives who worked with David A. Ramsay at Halozyme Therapeutics in 2013.
2013
Gregory Frost
Halozyme Therapeutics
Chief Executive Officer
2013
James Shaffer
Halozyme Therapeutics
Former Vice President and Chief Commercial Officer
2013
Jean Liu
Halozyme Therapeutics
General Counsel
2013
H Shepard
Halozyme Therapeutics
Chief Scientific Officer
2013
Kurt Gustafson
Halozyme Therapeutics